The agency greenlighted the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. Read this story
The agency greenlighted the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. Read this story
More from CNBC | Breaking news Health care industry Pharmaceuticals Biotech and Pharmaceuticals Biotechnology Business Pfizer Inc Science United States business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source